XTL Biopharmaceuticals Lt... (XTLB)
XTL Biopharmaceuticals Statistics
Share Statistics
XTL Biopharmaceuticals has 8.81M shares outstanding. The number of shares has increased by 191.25% in one year.
| Shares Outstanding | 8.81M |
| Shares Change (YoY) | 191.25% |
| Shares Change (QoQ) | 15.9% |
| Owned by Institutions (%) | 0.04% |
| Shares Floating | 8.6M |
| Failed to Deliver (FTD) Shares | 93 |
| FTD / Avg. Volume | 1.74% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
| Short Interest | - |
| Short % of Shares Out | null% |
| Short % of Float | null% |
| Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is -3088.68 and the forward PE ratio is null. XTL Biopharmaceuticals's PEG ratio is 30.89.
| PE Ratio | -3088.68 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 2.48 |
| P/FCF Ratio | -7.79 |
| PEG Ratio | 30.89 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for XTL Biopharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.93, with a Debt / Equity ratio of 0.
| Current Ratio | 9.93 |
| Quick Ratio | 9.93 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-222.75 |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -53.69% in the last 52 weeks. The beta is 1.01, so XTL Biopharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.01 |
| 52-Week Price Change | -53.69% |
| 50-Day Moving Average | 1.33 |
| 200-Day Moving Average | 1.98 |
| Relative Strength Index (RSI) | 42.56 |
| Average Volume (20 Days) | 5.36K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -765K |
| Net Income | -1.78K |
| EBITDA | -764K |
| EBIT | -765K |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 1.4M in cash and 0 in debt, giving a net cash position of 1.4M.
| Cash & Cash Equivalents | 1.4M |
| Total Debt | 0 |
| Net Cash | 1.4M |
| Retained Earnings | -158.25M |
| Total Assets | 9.28M |
| Working Capital | -480K |
Cash Flow
In the last 12 months, operating cash flow was -707K and capital expenditures 0, giving a free cash flow of -707K.
| Operating Cash Flow | -707K |
| Capital Expenditures | 0 |
| Free Cash Flow | -707K |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XTLB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for XTLB.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Feb 10, 2017. It was a backward split with a ratio of 1:5.
| Last Split Date | Feb 10, 2017 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | -22.92 |
| Piotroski F-Score | 3 |